Eli Lilly plans $6B API plant in Alabama
Eli Lilly will build a $6 billion new facility in Huntsville, Ala., to manufacture active pharmaceutical ingredients for small molecule and peptide medicines, including the company’s oral GLP-1 candidate, orforglipron. The site will support domestic production of therapies and strengthen pharmaceutical supply chains, according to a Dec. 9 news release from the drugmaker. The project is […]
Aeroflow Health and Molina Healthcare Break Down Barriers to Nutrition and Diabetes Care in South Carolina
What You Should Know: – Aeroflow Health has launched a statewide partnership with Molina Healthcare of South Carolina to expand access to virtual nutrition counseling and diabetes self-management education (DSME) for Commercial and Medicare members. – The initiative is built to dismantle persistent access barriers by offering evidence-based metabolic and nutrition care at little to no cost, […]
The 26 Most Important Ideas For 2026
Thank you all so much for reading and subscribing to this newsletter. It’s been an absolute blast whose success in its first six months has tremendously exceeded my expectations. If you’re arriving for the first time and like what you see, please subscribe. A little life update: Last week, my wife delivered our second baby […]
Semaglutide Tied to 50% Lower Risk for Epilepsy in Diabetes
The GLP-1 RA, semaglutide, significantly reduces epilepsy risk in diabetes, and this protective signal is driven by pathways unrelated to improvements in A1c or body weight. Medscape Medical News
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Q3 2025 Earnings Call Transcript
Academy Sports and Outdoors, Inc. (NASDAQ:ASO) Q3 2025 Earnings Call Transcript December 9, 2025 Academy Sports and Outdoors, Inc. beats earnings expectations. Reported EPS is $1.14, expectations were $1.07. Operator: Good morning, and welcome to the Academy Sports and Outdoors Third Quarter Fiscal 2025 Results Conference Call. The call is being recorded, and all participants […]
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
Pfizer PFE announced that it is in-licensing exclusive global rights to develop, manufacture and commercialize YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) from YaoPharma, a subsidiary of China’s leading drugmaker, Shanghai Fosun Pharmaceutical. YP05002 is currently being evaluated in phase I for treating obesity. Once-daily oral small molecule GLP-1 RAs are believed to have the […]
GLP-1 Medications, Such as Ozempic, Zepbound, Show Little Effect on Cancer, Study Shows
WEDNESDAY, Dec. 10, 2025 — A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
Researchers analyzed 48 randomized trials including 94,245 adults who were overweight, obese or had…
New Ozempic-alternative diabetes pill burns fat without muscle loss, study suggests
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic. While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles. A study led by researchers at Karolinska Institutet and Stockholm University […]
The 2025 Libertarian Gift Guide: 28 Great Ideas for Apocalypse Preppers, Boozers, Self-Improvers—and More
Hello! Welcome to my Hallmark movie casting call. My vision is as follows. You: a busy careerist or parent or homemaker. The specifics aren’t important, other than your main personality trait, which is “busy.” Setting: the holidays, as I’ve been reliably informed that this is a requirement for Hallmark films. The drama: You are not […]
GLP-1: Threat or opportunity for manufacturers?